Oncolytics Biotech Inc T.ONC

RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

[Noteable]

July 15, 2024 - "While patent cliffs are looming for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a research note from Morgan Stanley. 

We continue to see the conditions as generally favorable for bolt-on M&A as large-cap pharma companies have balance sheet capacity and a need to acquire outer-year revenue," the Morgan Stanley team, led by Terence Flynn, Ph.D., wrote.

https://www.fiercepharma.com/pharma/firepower-aplenty-and-patent-cliffs-ahead-time-right-ma-activity-report


July 10, 2024 - " Last year, Bayer laid out an ambition to reach $10 billion in revenue from cancer drugs by 2030 and to become a top 10 oncology player. It’s a bold target considering none of the pharma division’s top 3 products last year were in oncology, while Nubeqa is expected to hit above $1 billion sales this year. So at last year’s ASCO annual meeting, Christine Roth, head of global commercialization at Bayer’s pharmaceutical division, told Fierce Pharma that Bayer would need a “midsize acquisition” to reach its revenue goal."

Roth agreed that $5 billion to $10 billion would be a good value estimate for a midsize M&A transaction. But she also said she’s not “putting a ring fence around the dollar value.” The deal would likely come with a later-stage drug, she added.

https://www.fiercepharma.com/pharma/bayer-largely-complete-layoffs-within-pharma-commercial-team-2024-exec

https://www.fiercepharma.com/pharma/bayer-needs-midsize-acquisition-reach-10b-cancer-drug-sales-goal-oncology-chief-says